Article: DRAXIS Launches Alertec for the Treatment of Narcolepsy.

Article: DRAXIS Files Zonegran(TM) with Canadian Drug Regulators.
Canadian Corporate News;  February 5, 2001 ;     700+ words ... ... intractable pain, and Zonegran(TM) have been filed with the Canadian regulatory authorities while Zelapar(TM) for Parkinson's Disease is being ... Eldepryl(R) for Parkinson's disease, Alertec(TM) for narcolepsy, and Zanaflex(R ...

Article: DRAXIS Receives Canadian Regulatory Approval For AlertecTM For ...
Business Wire;  March 1, 1999 ;     700+ words ... ... of Compliance (NOC) approving Alertec(TM) (modafinil) for the Canadian marketplace. Alertec(TM) is indicated for the symptomatic ... unexpected times and conditions. Alertec(TM) is an original, new medication ...

Article: DRAXIS Files Zonegran with Canadian Drug Regulators.
Business Wire;  February 5, 2001 ;     700+ words ... ... intractable pain, and Zonegran(TM) have been filed with the Canadian regulatory authorities while Zelapar(TM) for Parkinson's Disease is being ... Eldepryl(R) for Parkinson's disease, Alertec(TM) for narcolepsy, and Zanaflex(R ...

Article: Draxis Health Reports Highlights From Annual General Meeting.
Business Wire;  June 23, 1999 ;     700+ words ... ... 1999, the recent Canadian launch of Alertec(TM) the first new treatment for narcolepsy ... frovatriptan (migraine), NeuroBloc(TM) (cervical dystonia), Ziconotide (chronic pain), Zonegran(TM) (epileptic seizures) and Zelapar ...

Article: DRAXIS DIVESTS TIAMOL/KERASAL PRODUCT LINES TO TARO.(Brief ...
Biotech Financial Reports;  August 1, 2000 ;     700+ words ... ... include Mysoline(R) and Diastat(R) for epilepsy, Permax(R) and Eldepryl(R) for Parkinson's disease, Alertec(TM) for narcolepsy, and Zanaflex(R) for the treatment of spasticity associated with conditions such as multiple sclerosis ...

Article: DRAXIS Files Ziconotide Under Priority Review Process With ...
Canadian Corporate News;  June 8, 2001 ;     700+ words ... ... include Mysoline(R) and Diastat(R) for epilepsy, Permax(R) and Eldepryl(R) for Parkinson's disease, Alertec(TM) for narcolepsy, and Zanaflex(R) for the treatment of spasticity associated with conditions such as multiple sclerosis ...

Article: DRAXIS Completes Pharmaceutica Unit Divestiture Worth Estimated ...
Canadian Corporate News;  July 22, 2003 ;     700+ words ... ... division, including Canadian product rights for Alertec(R), Diastat(R), Hectorol(TM), Permax(R), and Zanaflex(R). DRAXIS ... quarter, net of transaction and related charges. Alertec is a registered trademark owned by Genelco S ...